Infection

Study	Country	Design		VE (95% CI)
Link-Gelles et al., 2022	USA	TN	 ■	0.43 (0.39, 0.46)
Huiberts et al., 2023	Holland	С		0.20 (-0.07, 0.40)
Link-Gelles et al., 2023	USA	TN		0.43 (0.29, 0.55)
Shrestha et al., 2023	USA	С	 	0.04 (-0.12, 0.18)
			-0.25 0 0.25 0.5 0.75 Vaccine Effectiveness (VE)	1

Hospitalization/Severe Disease

Study	Country	Design			VE (95% CI)
Surie et al., 2022	USA	TN		 ■ 	0.73 (0.52, 0.85)
Tenforde et al., 2023	USA	TN			0.48 (0.30, 0.62)
Andersson et al., 2023	Nordics	MC		├-■-	0.74 (0.69, 0.79)
Andersson et al., 2023	Nordics	MC		 ■ 	0.80 (0.70, 0.92)
Lin et al., 2023	USA	С			0.59 (0.44, 0.70)
Fabiani et al., 2023	Italy	С		 ■ 	0.59 (0.55, 0.63)
Arbel et al., 2023	Israel	С			0.81 (0.57, 0.92)
Poukka et al., 2023	Finland	С			0.57 (0.34, 0.67)
			-0.25 (O 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)	